logo
Viking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past Month

Viking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past Month

Yahoo01-04-2025
Viking Therapeutics has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the enrollment for its Phase 2 trial of VK2735, a dual agonist targeting obesity, and entered a significant manufacturing agreement with CordenPharma, focusing on securing long-term supply. Despite these advancements, market-wide apprehension over upcoming tariffs, coupled with a selloff impacting major indexes like the S&P 500 and Nasdaq, both enduring sharp monthly losses, may have influenced the downward trajectory of VKTX's share price over the specified period.
We've identified 5 risks for Viking Therapeutics (2 make us uncomfortable) that you should be aware of.
The latest GPUs need a type of rare earth metal called Terbium and there are only 20 companies in the world exploring or producing it. Find the list for free.
Viking Therapeutics' shares have surged to deliver a very large total return over the three-year period, marking a striking performance among its peers in the biotech industry. Despite the recent year's underperformance relative to both the market and sector, this impressive return in a longer timeframe reflects the company's endeavors in product development and strong future promise. Viking's focus on innovative treatments, such as the VK2735 obesity program, has been crucial. In particular, its recent completion of Phase 2 trial enrollment and a multi-year manufacturing agreement with CordenPharma targets a significant market opportunity.
Noteworthy corporate activities have bolstered this growth narrative. For instance, the promising results from the VK2809 clinical trial for NASH and positive clinical data presentations on VK2735 signal strong pipeline advancements. Even as Viking reported a US$109.96 million net loss in 2024, these product-centric milestones have helped maintain investor confidence amidst the high volatility, positioning Viking favorably for potential future expansions in metabolic disorder treatments.
Insights from our recent valuation report point to the potential undervaluation of Viking Therapeutics shares in the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:VKTX.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time12 minutes ago

  • Yahoo

Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Manufacturing company Nordson (NASDAQ:NDSN) will be reporting results this Wednesday afternoon. Here's what to look for. Nordson beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $682.9 million, up 5% year on year. It was a satisfactory quarter for the company, with EPS guidance for next quarter topping analysts' expectations but organic revenue in line with analysts' estimates. Is Nordson a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Nordson's revenue to grow 9.1% year on year to $721.7 million, improving from the 2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.63 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nordson has missed Wall Street's revenue estimates three times over the last two years. Looking at Nordson's peers in the professional tools and equipment segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lincoln Electric delivered year-on-year revenue growth of 6.6%, beating analysts' expectations by 5.1%, and Hillman reported revenues up 6.2%, topping estimates by 2.6%. Lincoln Electric traded up 7.8% following the results while Hillman was also up 22.9%. Read our full analysis of Lincoln Electric's results here and Hillman's results here. There has been positive sentiment among investors in the professional tools and equipment segment, with share prices up 4.8% on average over the last month. Nordson's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $251.80 (compared to the current share price of $215.93). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Analog Devices (ADI) Q2 Earnings: What To Expect
Analog Devices (ADI) Q2 Earnings: What To Expect

Yahoo

time12 minutes ago

  • Yahoo

Analog Devices (ADI) Q2 Earnings: What To Expect

Manufacturer of analog chips Analog Devices (NASDAQ:ADI) will be reporting results this Wednesday before market hours. Here's what to look for. Analog Devices beat analysts' revenue expectations by 5.2% last quarter, reporting revenues of $2.64 billion, up 22.3% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' adjusted operating income estimates. Is Analog Devices a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Analog Devices's revenue to grow 19.5% year on year to $2.76 billion, a reversal from the 24.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.95 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Analog Devices has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Analog Devices's peers in the analog semiconductors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Impinj's revenues decreased 4.5% year on year, beating analysts' expectations by 4.3%, and Universal Display reported revenues up 8.4%, topping estimates by 6.1%. Impinj traded up 26.2% following the results while Universal Display's stock price was unchanged. Read our full analysis of Impinj's results here and Universal Display's results here. Investors in the analog semiconductors segment have had steady hands going into earnings, with share prices flat over the last month. Analog Devices is down 3.5% during the same time and is heading into earnings with an average analyst price target of $254.16 (compared to the current share price of $232.10). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Closing Bell Movers: Palo Alto Networks jumps 5% on Q4 earnings beat
Closing Bell Movers: Palo Alto Networks jumps 5% on Q4 earnings beat

Business Insider

time26 minutes ago

  • Business Insider

Closing Bell Movers: Palo Alto Networks jumps 5% on Q4 earnings beat

In the opening hour of the evening session, U.S. equity futures are up slightly, with S&P 500, Nasdaq 100, and Dow Industrials all up 0.1%. Commodities are little changed, as WTI Crude Oil recovered from recent two-month lows above $62 and Metals traded flat – below $3,380 for gold and just above $38 per ounce for silver. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Monday's low-volume session across the major indices saw little momentum for either bulls and bears, with investors seemingly inclined to await the Jackson Hole address by Fed Chair Powell later this week as well as notable earnings from retailing giants – Home Depot (HD), Target (TGT), and Walmart (WMT) report on Tuesday, Wednesday, and Thursday. Industrials and Consumer Discretionary were the top performing sectors on the S&P 500 while the Real Estate sector lagged as Treasuries crept higher across the curve for the third consecutive session. Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Flexsteel Industries (FLXS) up 19.2% Palo Alto Networks (PANW) up 5.1%; CyberArk (CYBR) up 4.1% in sympathy DOWN AFTER EARNINGS – Fabrinet (FN) down 8.4% Nyxoah (NYXH) down 4.1% Blink Charging (BLNK) down 3.9% XP Inc. (XP) down 2.1% ALSO LOWER –

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store